updated 11/12/2010 9:42:20 AM ET 2010-11-12T14:42:20

Drug developer Pozen Inc. said Friday it will receive a $25 million milestone payment after British regulators granted marketing and pricing approval for Vimovo modified release tablets.

Vimovo aims to treat signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing ulcers associated with the use of non-steroid anti-inflammatory drugs. London-based AstraZeneca and Pozen, based in Chapel Hill, N.C., have been developing the drug since 2006.

Pozen said it will receive the payment within 20 days, and the company confirmed its year-end net income guidance of $21 million to $23 million.

The U.S. Food and Drug Administration approved Vimovo earlier this year.

Pozen shares rose 31 cents, or 4.7 percent, to $6.93 in morning trading.

Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com